• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

服用奥美沙坦的患者出现显著体重减轻：一例罕见病例报告。

Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.

作者信息

Makri Andromachi, Florentin Matilda, Elisaf Moses S, Liamis George

机构信息

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

出版信息

Curr Drug Saf. 2019;14(3):238-241. doi: 10.2174/1574886314666190307142111.

DOI:10.2174/1574886314666190307142111
PMID:30848210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6865051/
Abstract

OBJECTIVE

Olmesartan-induced enteropathy consists a syndrome that mimics celiac disease both clinically and histologically. Cases of this entity have sporadically been reported since 2012 and are usually characterized by severe diarrhea and malabsorption, followed by significant weight loss.

CASE REPORT

Herein, we report an uncommon case of this syndrome, where weight loss preceded several months the onset of gastrointestinal symptoms.

DISCUSSION AND CONCLUSION

Physicians should be aware of unexplained weight loss in patients taking olmesartan, as prompt discontinuation of the drug may prevent the deleterious consequences of malabsorption.

摘要

目的

奥美沙坦诱发的肠病是一种在临床和组织学上都类似于乳糜泻的综合征。自2012年以来，偶尔有该病症的病例报告，其通常的特征是严重腹泻和吸收不良，随后体重显著减轻。

病例报告

在此，我们报告该综合征的一例罕见病例，体重减轻发生在胃肠道症状出现前几个月。

讨论与结论

医生应意识到服用奥美沙坦的患者出现不明原因的体重减轻，因为及时停药可能会预防吸收不良的有害后果。

相似文献

1
Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.服用奥美沙坦的患者出现显著体重减轻：一例罕见病例报告。
Curr Drug Saf. 2019;14(3):238-241. doi: 10.2174/1574886314666190307142111.
2
Olmesartan-Induced Enteropathy.奥美沙坦所致小肠病
Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):230-232. doi: 10.14797/mdcj-12-4-230.
3
Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss.奥美沙坦相关肠病：腹泻和体重减轻的一种罕见的漏诊病因。
Am J Case Rep. 2019 Jan 26;20:111-116. doi: 10.12659/AJCR.913207.
4
[Three cases of severe chronic diarrhea with a rare cause and a simple therapy].[三例病因罕见且治疗简单的严重慢性腹泻病例]
Internist (Berl). 2018 Sep;59(9):961-966. doi: 10.1007/s00108-018-0417-2.
5
Duodenal Villous Atrophy in a TTG-Negative Patient Taking Olmesartan: A Case Report and Review of the Literature.服用奥美沙坦的 TTG 阴性患者的十二指肠绒毛萎缩：病例报告及文献复习。
Can J Gastroenterol Hepatol. 2016;2016:6091571. doi: 10.1155/2016/6091571. Epub 2016 Apr 14.
6
Olmesartan enteropathy: an important cause of malabsorption and diarrhoea.奥美沙坦肠病：吸收不良和腹泻的重要原因。
Intern Med J. 2020 Jan;50(1):130-132. doi: 10.1111/imj.14661.
7
[An unusual case of olmesartan induced enteropathy].[一例罕见的奥美沙坦诱导的肠病]
Ann Pathol. 2019 Jun;39(3):237-240. doi: 10.1016/j.annpat.2018.10.007. Epub 2019 Feb 1.
8
Olmesartan: sprue-like enteropathy.奥美沙坦：类口炎性腹泻样小肠病。
Prescrire Int. 2014 Apr;23(148):102.
9
Olmesartan-induced enteropathy.奥美沙坦所致肠病
BMJ Case Rep. 2018 Oct 2;2018:bcr-2018-224411. doi: 10.1136/bcr-2018-224411.
10
Olmesartan-induced enteropathy treated with budesonide.布地奈德治疗奥美沙坦所致肠病
Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):319-321.

引用本文的文献

1
Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System.使用美国食品药品监督管理局不良事件报告系统比较高血压患者中血管紧张素受体阻滞剂的不良事件
Cureus. 2025 Apr 8;17(4):e81912. doi: 10.7759/cureus.81912. eCollection 2025 Apr.

本文引用的文献

1
[An unusual case of olmesartan induced enteropathy].[一例罕见的奥美沙坦诱导的肠病]
Ann Pathol. 2019 Jun;39(3):237-240. doi: 10.1016/j.annpat.2018.10.007. Epub 2019 Feb 1.
2
Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss.奥美沙坦相关肠病：腹泻和体重减轻的一种罕见的漏诊病因。
Am J Case Rep. 2019 Jan 26;20:111-116. doi: 10.12659/AJCR.913207.
3
Olmesartan-induced enteropathy.奥美沙坦所致肠病
BMJ Case Rep. 2018 Oct 2;2018:bcr-2018-224411. doi: 10.1136/bcr-2018-224411.
4
Olmesartan-associated enteropathy. A rare but easily treatable entity.
Acta Gastroenterol Belg. 2017 Oct-Dec;80(4):541-543.
5
Use of olmesartan and enteropathy outcomes: a multi-database study.使用奥美沙坦和肠病结局：一项多数据库研究。
Aliment Pharmacol Ther. 2018 Mar;47(6):792-800. doi: 10.1111/apt.14518. Epub 2018 Jan 22.
6
A Case of Olmesartan-associated Sprue-like Enteropathy.
Clin Gastroenterol Hepatol. 2018 Oct;16(10):A45-A46. doi: 10.1016/j.cgh.2017.12.015. Epub 2017 Dec 13.
7
A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan.一例与替米沙坦相关的中度类口炎性腹泻样小肠病病例。
J Clin Med Res. 2017 Dec;9(12):1022-1025. doi: 10.14740/jocmr3047w. Epub 2017 Nov 6.
8
Sprue-Like Enteropathy Associated with Olmesartan: An Unrecognized Emerging Drug-Induced Enteropathy?与奥美沙坦相关的类口炎性腹泻样小肠病：一种未被认识的新出现的药物性小肠病？
GE Port J Gastroenterol. 2016 Oct 13;23(6):335-336. doi: 10.1016/j.jpge.2016.06.004. eCollection 2016 Nov-Dec.
9
Olmesartan-Induced Sprue Like Enteropathy.奥美沙坦诱导的类口炎性腹泻样小肠病。
GE Port J Gastroenterol. 2016 Jan 14;23(2):101-105. doi: 10.1016/j.jpge.2015.12.003. eCollection 2016 Mar-Apr.
10
Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block.与奥美沙坦相关的类口炎性腹泻性肠病：肠病领域的新成员。
GE Port J Gastroenterol. 2016 Mar 28;23(2):61-65. doi: 10.1016/j.jpge.2016.02.005. eCollection 2016 Mar-Apr.